Cargando…

Protected risk stratification with the wearable cardioverter-defibrillator: results from the WEARIT-II-EUROPE registry

BACKGROUND: The prospective WEARIT-II-EUROPE registry aimed to assess the value of the wearable cardioverter-defibrillator (WCD) prior to potential ICD implantation in patients with heart failure and reduced ejection fraction considered at risk of sudden arrhythmic death. METHODS AND RESULTS: 781 pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Veltmann, Christian, Winter, Stefan, Duncker, David, Jungbauer, Carsten G., Wäßnig, Nadine K., Geller, J. Christoph, Erath, Julia W., Goeing, Olaf, Perings, Christian, Ulbrich, Michael, Roser, Mattias, Husser, Daniela, Gansera, Laura S., Soezener, Korkut, Malur, Frank Michael, Block, Michael, Fetsch, Thomas, Kutyifa, Valentina, Klein, Helmut U.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7806570/ https://www.ncbi.nlm.nih.gov/pubmed/32377784 http://dx.doi.org/10.1007/s00392-020-01657-2

Ejemplares similares

Correction to: Protected risk stratification with the wearable cardioverter-defibrillator: results from the WEARIT-II-EUROPE registry
por: Veltmann, Christian, et al.
Publicado: (2020)

Avoiding Untimely Implantable Cardioverter/Defibrillator Implantation by Intensified Heart Failure Therapy Optimization Supported by the Wearable Cardioverter/Defibrillator—The PROLONG Study
por: Duncker, David, et al.
Publicado: (2017)

Wearable cardioverter-defibrillator in patients with a transient risk of sudden cardiac death: the WEARIT-France cohort study
por: Garcia, Rodrigue, et al.
Publicado: (2020)

Usage of the wearable cardioverter-defibrillator during pregnancy
por: Olic, J.-Jacqueline, et al.
Publicado: (2022)

Depressive Symptoms and Quality of Life in Patients With Heart Failure and an Implantable Cardioverter-Defibrillator
por: Zormpas, Christos, et al.
Publicado: (2022)

Premature end of service of implantable cardioverter-defibrillator by magnetic interference with left-ventricular assist device
por: Eiringhaus, Jörg, et al.
Publicado: (2021)

Eligibility for subcutaneous implantable cardioverter-defibrillator in patients with left ventricular assist device
por: Zormpas, Christos, et al.
Publicado: (2020)

Dynamic changes in nocturnal heart rate predict short-term cardiovascular events in patients using the wearable cardioverter-defibrillator: from the WEARIT-France cohort study
por: Garcia, Rodrigue, et al.
Publicado: (2023)

Eligibility for subcutaneous implantable cardioverter‐defibrillator in adults with congenital heart disease
por: Zormpas, Christos, et al.
Publicado: (2021)

Experience With the Wearable Cardioverter-Defibrillator in Patients at High Risk for Sudden Cardiac Death
por: Wäßnig, Nadine K., et al.
Publicado: (2016)

Extended follow‐up after wearable cardioverter‐defibrillator period: the PROLONG‐II study
por: Mueller‐Leisse, Johanna, et al.
Publicado: (2021)

Role of the Wearable Defibrillator in Newly Diagnosed Heart Failure
por: Duncker, David, et al.
Publicado: (2018)

Defibrillators for prevention from sudden cardiac death: is it that easy?
por: Duncker, David, et al.
Publicado: (2020)

Changes in eligibility for a subcutaneous cardioverter-defibrillator after implantation of a left ventricular assist device–A prospective analysis
por: Zormpas, Christos, et al.
Publicado: (2023)

Feasibility and First Results of Heart Failure Monitoring Using the Wearable Cardioverter–Defibrillator in Newly Diagnosed Heart Failure with Reduced Ejection Fraction
por: Hillmann, Henrike Aenne Katrin, et al.
Publicado: (2021)

Secondary prevention implantable cardioverter-defibrillator (ICD) therapy: value in octogenarians
por: Hauck, Christian, et al.
Publicado: (2021)

Extended use of the wearable cardioverter-defibrillator in patients at risk for sudden cardiac death
por: Kutyifa, Valentina, et al.
Publicado: (2018)

Publisher Erratum: The Heart Failure Optimization Study (HF‑OPT): rationale and design
por: Sanchez, R., et al.
Publicado: (2023)

The Heart Failure Optimization Study (HF-OPT): rationale and design
por: Sanchez, R., et al.
Publicado: (2023)

Outcome by Sex in Patients With Long QT Syndrome With an Implantable Cardioverter Defibrillator
por: Younis, Arwa, et al.
Publicado: (2020)

Need for pacing in patients who qualify for an implantable cardioverter‐defibrillator: Clinical implications for the subcutaneous ICD
por: Kutyifa, Valentina, et al.
Publicado: (2020)

Real life experience with the wearable cardioverter-defibrillator in an international multicenter Registry
por: El-Battrawy, Ibrahim, et al.
Publicado: (2022)

Critical appraisal concerning “Wearable cardioverter defibrillators for the prevention of sudden cardiac arrest: a health technology assessment and patient focus group study”
por: Sperzel, Johannes, et al.
Publicado: (2018)

Critical analysis of ineffective post implantation implantable cardioverter-defibrillator-testing
por: Roos, Markus, et al.
Publicado: (2017)

Antiarrhythmic effects of baroreceptor activation therapy in chronic heart failure: a case report
por: Wang, Dong, et al.
Publicado: (2023)

Subcutaneous implantable cardioverter-defibrillator generator removal: a multicenter analysis
por: Luker, J, et al.
Publicado: (2023)

Comments on the authors’ reply to the critical appraisal concerning “Wearable cardioverter defibrillators for the prevention of sudden cardiac arrest: a health technology assessment and patient focus group study”
por: Sperzel, Johannes, et al.
Publicado: (2018)

Quality of Life in Patients with Implantable Cardioverter Defibrillators
por: Francis, Johnson, et al.
Publicado: (2006)

Effect of cardiac resynchronization therapy with implantable cardioverter defibrillator versus cardiac resynchronization therapy with pacemaker on mortality in heart failure patients: results of a high-volume, single-centre experience
por: Kutyifa, Valentina, et al.
Publicado: (2014)

Implantable cardioverter-defibrillators /
Publicado: (1994)

Ventricular arrhythmia burden in patients with implantable cardioverter defibrillator and remote patient monitoring during different time intervals of the COVID-19 pandemic
por: Hauck, Christian, et al.
Publicado: (2022)

Ability to remotely monitor atrial high-rate episodes using a single-chamber implantable cardioverter-defibrillator with a floating atrial sensing dipole
por: Hindricks, Gerhard, et al.
Publicado: (2023)

Wearable cardioverter defibrillator: Bridge or alternative to implantation?
por: Barraud, Jeremie, et al.
Publicado: (2017)

Implantable cardioverter-defibrillator programming after first occurrence of ventricular tachycardia in the Multicenter Automatic Defibrillator Implantation Trial–Reduce Inappropriate Therapy (MADIT-RIT)
por: Aktas, Mehmet K., et al.
Publicado: (2020)

The Automatic External Cardioverter-Defibrillator
por: Martínez-Rubio, Antoni, et al.
Publicado: (2004)

Deactivation of implantable cardioverter-defibrillators
por: Wan, Darryl, et al.
Publicado: (2021)

Quarterly vs. yearly clinical follow-up of remotely monitored recipients of prophylactic implantable cardioverter-defibrillators: results of the REFORM trial
por: Hindricks, Gerhard, et al.
Publicado: (2014)

Primary prevention implantable cardioverter defibrillator in cardiac resynchronization therapy recipients with advanced chronic kidney disease
por: Goldenberg, Ido, et al.
Publicado: (2023)

The subcutaneous implantable cardioverter-defibrillator should be considered for all patients with an implantable cardioverter-defibrillator indication
por: Tan, Jian Liang, et al.
Publicado: (2022)

Longevity of implantable cardioverter defibrillators: a comparison among manufacturers and over time
por: von Gunten, Simon, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_dakntta920io33i7dt42ltfkod